Funding Programs

CTSI Accelerator collaborates with partners at Duke and other institutions to provide researchers with funding opportunities for the entire translational spectrum.

Don't see a funding opportunity that fits your needs? Contact our team to get personalized assistance finding appropriate funding sources.

      Latest Funding Announcements      

  FAQs for Pilot Program Funding   

       View Past Award Winners       


CTSI Translational Accelerator Funding Agreements (CTSI Accelerator)

  • Up to $150,000
  • Purpose: Support for cross-disciplinary scientific research addressing the development of therapies, diagnostics or devices applicable to human disease, clinical research/trials (excluding Phase 2 or beyond), epidemiological studies, and/or community-based research.

Status: Applications for 2018 are now open.

  Learn more and view the RFA  


CTSI Transformative Research Agreements (CTSI Accelerator)

  • Up to $500,000
  • Purpose: Support development of mature research with the potential to attract significant interest for external partnering, thus enabling and accelerating translation of research out of the academic environment (i.e. new company formation, license, or partnership).

Status: Applications for the 2019-2021 cycle are now open.

  Learn more and view the RFA  


Duke/RTI Collaborative Translational Research Grants (CTSI Accelerator)

  • up to $25,000 per institution ($50,000 total)
  • Purpose: Develop inter-institutional collaborations for new investigator teams conducting novel clinical and translational research that applies or accelerates discovery into testing in clinical or population settings.

Status: 2018 application period is closed. The deadline for Letters of Intent was August 13, 2018.

  Learn more and view the RFA  


CTSI Special Populations Pilot Agreements (CTSI Accelerator)

  • up to $25,000
  • Purpose: Facilitate research that promotes health equity for groups who have traditionally been under-represented in health research or excluded altogether.

Status: 2018 application period is closed. The deadline for Letters of Intent was September 17, 2018.

  Learn more and view the RFA  


Duke/UNC-Chapel Hill CTSA Consortium Collaborative (CTSI Accelerator)

  • $25,000 per institution ($50,000 total)
  • Purpose: Develop inter-institutional collaborations for new investigator teams conducting novel clinical and translational research that applies or accelerates discovery into testing in clinical or population settings.

Status: The 2018 application period closed in October. Please check back in 2019 for new dates. 

  Learn more and view the RFA  


  • Up to $25,000 per institution ($50,000 total)
  • Purpose: To support new inter-institutional collaborative research projects between Duke University and North Carolina Central University investigators.

Status: The 2018 application period closed in October. Please check back in 2019 for new dates. 

Optional Letter of Intent due September 28, 2018.

  Learn more and view the RFA  


Carolinas Collaborative (CTSI Accelerator)

  • $25,000 per institution
  • Purpose: CTSAs at Duke, the Medical University of South Carolina, UNC-CH, and Wake Forest, have partnered with Health Sciences South Carolina to create a pilot program designed to encourage and facilitate novel clinical and translational research that applies or accelerates discovery into testing in clinical or population settings. The research must use the component electronic health record data warehouses from at least two of the four CTSAs.

2018 Application period closed August 15, 2018. 

Key Application Dates

  • Informational Webinar: June 29, 2018 | 10:00–11:00 a.m. 
  • Application Submission Deadline: August 15, 2018 at 5:00 p.m.
  • Selection of Awardees: by September 30, 2018
  • Funding period: 12 months beginning no more than 60 days after notification of the award and ending no later than November 30, 2019.

View and download the RFA here.

Register for the informational webinar here.

​The slides will be made available for anyone who cannot join this optional educational event.
 

Duke/NC State Translational Research Grant (CTSI Accelerator)

  • Up to $25,000 per institution ($50,000 total)
  • Purpose: Develop inter-institutional collaborations for new investigator teams conducting novel clinical and translational research that applies or accelerates discovery into testing in clinical or population settings.

Status: 2018 Application period closed May 15, 2018.

Learn more and view the RFA


Children’s Health & Discovery Initiative (CHDI)/MEDx Pilot Research Grant

  • Up to $50,000 to one research team that includes one PI from the School of Medicine and one PI from Pratt School of Engineering
  • Purpose: To support pilot studies that lead to the development of diagnostics, prognostics, or biomarkers for early life risk factors for disease or biological processes associated with diseases that initiate early in life, or methods/technologies to detect exposures that influence childhood or life-long health.

Status: 2018 Application period closed June 5, 2018.

 View the RFP 

 


Duke-Coulter Translational Partnership Grants

  • No fixed award limit.  Approximately $700,000 is available annually to fund ~3-5 projects
  • Purpose: Support collaborative translational research projects that involve co-investigators from the Duke University Department of Biomedical Engineering and a clinical department in the Duke University Health System.

Status: The 2018 application period closed March 9, 2018. Applications will reopen in December 2018 for 2019 funding.


CTSI Population Health Improvement Awards

  • Three-tiered program with awards from $1,000 to $25,000
  • Purpose: Seed, Co-development, and Advanced Partnership Awards to stimulate and foster community-research partnerships that advance solutions to improve local health and healthcare delivery. 

Status: The 2018 application period closed February 22, 2018. Applications will reopen in early 2019.

 

 

 

 

The CTSI Pilot Programs are funded primarily through Duke’s National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS) Clinical and Translational Science Award (CTSA) UL1TR002553.